Debt-to-equity of Monopar Therapeutics from 30 Sep 2018 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Monopar Therapeutics quarterly Debt-to-equity in % history and change rate from 30 Sep 2018 to 30 Sep 2025.
  • Monopar Therapeutics Debt-to-equity for the quarter ending 30 Sep 2025 was 3.6%, a 84% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Monopar Therapeutics Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 3.6% -19% -84% 30 Sep 2025
Q2 2025 5.8% -19% -76% 30 Jun 2025
Q1 2025 7.5% -20% -73% 31 Mar 2025
Q4 2024 12% -19% -62% 31 Dec 2024
Q3 2024 22% -9% -29% 30 Sep 2024
Q2 2024 24% -2.3% -8.5% 30 Jun 2024
Q1 2024 28% +5.8% +26% 31 Mar 2024
Q4 2023 32% +16% +103% 31 Dec 2023
Q3 2023 31% +21% +189% 30 Sep 2023
Q2 2023 27% +18% +210% 30 Jun 2023
Q1 2023 22% +16% +254% 31 Mar 2023
Q4 2022 16% 31 Dec 2022
Q3 2022 11% 30 Sep 2022
Q2 2022 8.6% 30 Jun 2022
Q1 2022 6.2% 31 Mar 2022
Q4 2020 5.1% -2.9% -37% 31 Dec 2020
Q3 2020 4.5% -4.1% -47% 30 Sep 2020
Q2 2020 5.5% -1.4% -21% 30 Jun 2020
Q1 2020 6.1% +0.41% +7.2% 31 Mar 2020
Q4 2019 8% +3.8% +90% 31 Dec 2019
Q3 2019 8.6% +5% +138% 30 Sep 2019
Q2 2019 6.9% 30 Jun 2019
Q1 2019 5.7% 31 Mar 2019
Q4 2018 4.2% 31 Dec 2018
Q3 2018 3.6% 30 Sep 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.